Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
19(R)-hydroxyprostaglandin E2 is a naturally occurring lipid mediator and an analog of Prostaglandin E2 (PGE2), primarily identified in the semen of primates, including humans. It functions as a potent and selective agonist for the Prostaglandin E2 receptor EP2 subtype. As a small molecule, it is widely utilized as a chemical research tool to investigate the physiological and pathological roles of the EP2 receptor pathway, particularly its involvement in smooth muscle relaxation, inflammation, vascular tone regulation, and immune response modulation. The compound is commercialized by specialized chemical suppliers such as Cayman Chemical and MedChemExpress for laboratory research purposes only and is not approved for human or veterinary therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 19(R)-hydroxyprostaglandin E2.